COX-2 inhibitors and the gastrointestinal tract.
Bjarnason
I
I
Department of Medicine, Guy's, King's, St Thomas' Medical School, London, UK. ingvar.bjsrmason@kcl.ac.uk
Rainsford
K D
KD
D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D000068579:Celecoxib; D051546:Cyclooxygenase 2; D004347:Drug Interactions; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects*; D007527:Isoenzymes / Q000037:antagonists & inhibitors*; D007783:Lactones / Q000494:pharmacology*; D008565:Membrane Proteins; D011451:Prostaglandin-Endoperoxide Synthases; D011720:Pyrazoles; D012377:Rodentia; D013449:Sulfonamides / Q000494:pharmacology*; D013450:Sulfones
D007527:Isoenzymes; D007783:Lactones; D008565:Membrane Proteins; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases; D000068579:Celecoxib; D001241:Aspirin